What Is Retatrutide? Mechanism, Trial Evidence & UK Status

An evidence-based overview of retatrutide — the first-in-class triple hormone receptor agonist — covering how it is studied to work, the published clinical-trial data, and its research-use-only status in the UK.

8 min read · Published 2026-06-23

What Is Retatrutide?

Retatrutide (developmental code LY3437943) is a synthetic peptide developed by Eli Lilly. The scientific literature describes it as a single molecule conjugated to a fatty-diacid moiety that simultaneously activates three metabolic receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This "triple agonist" design distinguishes it from GLP-1 mono-agonists such as semaglutide and GLP-1/GIP dual agonists such as tirzepatide.

Research use only. Material supplied as a research peptide is intended for in-vitro laboratory use. It is not a medicine and is not for human or veterinary consumption, administration, or therapeutic use.

How Retatrutide Is Studied to Work

In published research each receptor target is associated with a distinct effect:

  • GLP-1 receptor — appetite signalling and slowed gastric emptying in study models.
  • GIP receptor — insulin sensitivity and adipose-tissue modulation.
  • Glucagon receptor — energy expenditure and fat oxidation.

Cell-culture data indicate retatrutide is somewhat less potent than the body's own ligands at the human glucagon and GLP-1 receptors and more potent at the GIP receptor. Reported pharmacokinetics describe an approximate six-day half-life in clinical study, which supported once-weekly subcutaneous administration in trial settings.

The Clinical-Trial Evidence

Retatrutide has progressed from Phase 2 into a Phase 3 programme. A Phase 2 obesity trial published in the New England Journal of Medicine (2023) reported body-weight reductions of up to roughly 24% over 48 weeks at the highest doses studied. Eli Lilly's Phase 3 TRIUMPH programme comprises multiple trials; readouts reported in 2025–2026 described mean weight reductions of approximately 28% at 68–80 weeks.

These outcomes come from controlled clinical trials conducted under medical supervision in defined patient populations. They are presented here for scientific context only — they are not claims about research-grade material and do not constitute medical advice.

Is Retatrutide Approved? UK & Global Regulatory Status

As of 2026, retatrutide is not approved for any indication by any regulator worldwide, including the UK's MHRA, the European EMA, and the US FDA. It is an investigational compound that is accessible to humans only through authorised clinical trials. In April 2026 the MHRA publicly highlighted that unlicensed peptide products marketed with health claims are a regulatory concern. Material sold by research suppliers is therefore strictly research-use-only.

Research Handling & Quality Considerations

As a lyophilised (freeze-dried) peptide, retatrutide is typically kept frozen and reconstituted with bacteriostatic water for in-vitro work — see our reconstitution guide and storage guide. Because purity directly affects experimental reliability, identity and purity should be verified against a batch-matched Certificate of Analysis (COA) with HPLC and mass-spectrometry data.

Retatrutide vs Tesamorelin and Other Metabolic Peptides

Retatrutide is an investigational incretin triple agonist. By contrast, tesamorelin is a GHRH analogue that acts on an entirely different pathway (the growth-hormone axis). Browse the full metabolic research peptides range, or view retatrutide product details and COA.

Frequently Asked Questions

Is retatrutide approved in the UK?

No. Retatrutide has no marketing authorisation from the MHRA or any other regulator as of 2026. It is investigational and supplied only for laboratory research use.

What makes retatrutide a 'triple agonist'?

It is a single peptide that activates three receptors at once — GLP-1, GIP, and glucagon — whereas earlier compounds activate one or two.

Can I use retatrutide for weight loss?

No. Research-grade retatrutide is for in-vitro laboratory use only and is not for human consumption. Clinical-trial results were obtained under medical supervision and do not apply to research material.

How is retatrutide stored?

As a lyophilised peptide it is kept frozen and reconstituted with bacteriostatic water for research use. See our storage and reconstitution guides.

Related Guides

Browse research peptides or read more research guides.